Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

[1]  R. Warnke,et al.  Anaplastic Large‐Cell Lymphoma , 2011 .

[2]  A. Kohlmann,et al.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.

[3]  L. Federici,et al.  Folding mechanism of the C‐terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  D. Alonso,et al.  Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity , 2009, Molecular Cancer Therapeutics.

[5]  S. Pileri,et al.  A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF , 2009, Leukemia.

[6]  M. Komada,et al.  Nucleolar structure and function are regulated by the deubiquitylating enzyme USP36 , 2009, Journal of Cell Science.

[7]  W. Hiddemann,et al.  Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor , 2009, British journal of haematology.

[8]  R. Foà,et al.  Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability , 2009, Haematologica.

[9]  S. Mutka,et al.  Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.

[10]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[11]  Peter Gregor,et al.  NOPdb: Nucleolar Proteome Database—2008 update , 2008, Nucleic Acids Res..

[12]  Yuh Min Chook,et al.  Structural basis for leucine-rich nuclear export signal recognition by CRM1 , 2009, Nature.

[13]  N. Bolli,et al.  A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia , 2008, Leukemia.

[14]  K. Döhner,et al.  Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG) , 2008 .

[15]  G. Ehninger,et al.  A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML). , 2008 .

[16]  T. Haferlach,et al.  Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy , 2008 .

[17]  K. Döhner,et al.  Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation , 2008 .

[18]  R. Hills,et al.  The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial , 2008 .

[19]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[20]  P. Pandolfi,et al.  Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome , 2008, Molecular and Cellular Biology.

[21]  W. Du,et al.  TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. , 2008, Blood.

[22]  P. Pelicci,et al.  A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth , 2008, Nature Cell Biology.

[23]  M. Bycroft,et al.  Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia* , 2008, Journal of Biological Chemistry.

[24]  P. P. D. Fiore.  Playing both sides: nucleophosmin between tumor suppression and oncogenesis , 2008 .

[25]  P. Pelicci,et al.  Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ , 2008, The Journal of cell biology.

[26]  B Falini,et al.  In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML , 2008, Leukemia.

[27]  G. Martinelli,et al.  Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations , 2008, Leukemia.

[28]  G. Wertheim,et al.  Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. , 2008, The Journal of molecular diagnostics : JMD.

[29]  D. Hernandez-Verdun,et al.  In nucleoli, the steady state of nucleolar proteins is leptomycin B‐sensitive , 2008, Biology of the cell.

[30]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[31]  S. Pileri,et al.  Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice , 2008, Haematologica.

[32]  T. Lim,et al.  Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. , 2008, Journal of molecular biology.

[33]  J. Clohessy,et al.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. , 2008, Blood.

[34]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[35]  G. Montelione,et al.  The solution structure of ribosomal protein S17E from Methanobacterium thermoautotrophicum: A structural homolog of the FF domain , 2008, Protein science : a publication of the Protein Society.

[36]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[37]  S. Scholl,et al.  Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia , 2008, European journal of haematology.

[38]  G. Specchia,et al.  Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules , 2008, Leukemia.

[39]  M. Okuwaki,et al.  The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. , 2007, Journal of biochemistry.

[40]  R. Arceci.  Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification , 2007 .

[41]  D. Hernandez-Verdun,et al.  Nucleolus: the fascinating nuclear body , 2007, Histochemistry and Cell Biology.

[42]  J. Clohessy,et al.  The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence , 2007, Oncogene.

[43]  B. Falini,et al.  Selective Silencing of the NPM1 Mutant Protein and Apoptosis Induction upon ATRA In Vitro Treatment of AML Cells Carrying NPM1 Mutations. , 2007 .

[44]  T. Misteli.  Physiological importance of RNA and protein mobility in the cell nucleus , 2007, Histochemistry and Cell Biology.

[45]  J. Wulff,et al.  The natural product avrainvillamide binds to the oncoprotein nucleophosmin. , 2007, Journal of the American Chemical Society.

[46]  M. Baccarani,et al.  NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia , 2007, Haematologica.

[47]  N. Bolli,et al.  Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif , 2007, Leukemia.

[48]  S. Pileri,et al.  Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas , 2007, Leukemia.

[49]  Brunangelo Falini,et al.  Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. , 2007, Cancer research.

[50]  S. Elledge,et al.  The ubiquitin-specific protease USP28 is required for MYC stability , 2007, Nature Cell Biology.

[51]  J. Chen,et al.  Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival , 2007, Proceedings of the National Academy of Sciences.

[52]  N. Bolli,et al.  Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation , 2007, Leukemia.

[53]  M. Balbín,et al.  A new type of NPM1 gene mutation in AML leading to a C-terminal truncated protein , 2007, Leukemia.

[54]  Brunangelo Falini,et al.  Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. , 2007, Haematologica.

[55]  N. Yoo,et al.  Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[56]  M. Yao,et al.  Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.

[57]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[58]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[59]  J. Ausió,et al.  New insights into the nucleophosmin/nucleoplasmin family of nuclear chaperones , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[60]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[61]  Myriam Alcalay,et al.  Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. , 2006, Blood.

[62]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[63]  M. Olson,et al.  Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23 , 2006, Journal of Cell Science.

[64]  P. Pelicci,et al.  Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal , 2006, Oncogene.

[65]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[66]  N. Bolli,et al.  Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML , 2006, Leukemia.

[67]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[68]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[69]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[70]  M. Dai,et al.  Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export , 2006, Molecular and Cellular Biology.

[71]  N. Bolli,et al.  Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. , 2006, The Lancet. Oncology.

[72]  R. Gjerset,et al.  Regulation of p14ARF Through Subnuclear Compartmentalization , 2006, Cell cycle.

[73]  P. Pelicci,et al.  Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. , 2006, Cancer research.

[74]  M. Yao,et al.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.

[75]  Hitoshi Suzuki,et al.  Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre‐mRNA processing , 2006, FEBS letters.

[76]  R. Kefford,et al.  The ARF tumour suppressor. , 2006, The international journal of biochemistry & cell biology.

[77]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM 1 mutations in 1485 adult patients with acute myeloid leukemia ( AML ) , 2006 .

[78]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[79]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[80]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[81]  B. Falini,et al.  Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability , 2005, Molecular and Cellular Biology.

[82]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[83]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[84]  C. Sherr,et al.  Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein , 2005, Cell cycle.

[85]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[86]  X. Wang,et al.  Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication , 2005, Nature Cell Biology.

[87]  R. Suzuki,et al.  Nucleophosmin in acute myelogenous leukemia. , 2005, The New England journal of medicine.

[88]  Y. Lam,et al.  The Nucleolus , 2016, Methods in Molecular Biology.

[89]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[90]  S. Lockett,et al.  Kinetic and Molecular Analysis of Nuclear Export Factor CRM1 Association with Its Cargo In Vivo , 2005, Molecular and Cellular Biology.

[91]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[92]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[93]  Mei-Ling Kuo,et al.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor. , 2004, Genes & development.

[94]  Charles J. Sherr,et al.  Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23 , 2004, Molecular and Cellular Biology.

[95]  Pamela A. Silver,et al.  Nuclear transport and cancer: from mechanism to intervention , 2004, Nature Reviews Cancer.

[96]  R. Ochs,et al.  Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23 , 2004, Chromosoma.

[97]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[98]  J. Yun,et al.  Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix , 2003, Journal of cellular biochemistry.

[99]  Søren Brunak,et al.  NESbase version 1.0: a database of nuclear export signals , 2003, Nucleic Acids Res..

[100]  W. Hiddemann,et al.  Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy , 2002, Leukemia.

[101]  Florence Dalenc,et al.  Increased expression of a COOH‐truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells , 2002, International journal of cancer.

[102]  Dominique Ploton,et al.  Three-dimensional organization of active rRNA genes within the nucleolus. , 2002, Journal of cell science.

[103]  K. Nagata,et al.  The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. , 2002, Molecular biology of the cell.

[104]  B. Falini,et al.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.

[105]  H. Umekawa,et al.  Tryptophans 286 and 288 in the C-terminal Region of Protein B23.1 are Important for Its Nucleolar Localization , 2002, Bioscience, biotechnology, and biochemistry.

[106]  J. Bennett,et al.  B-Lymphoblastic Leukemia/Lymphoma , 2014 .

[107]  F. Birg,et al.  Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Mole , 2000, Blood.

[108]  M. Olson,et al.  Mapping the Functional Domains of Nucleolar Protein B23* , 2000, The Journal of Biological Chemistry.

[109]  B. Henderson,et al.  A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. , 2000, Experimental cell research.

[110]  E. Campo,et al.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. , 1999, Blood.

[111]  N. Kudo,et al.  Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[112]  A. Partin,et al.  Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4‐216) recognizes nucleophosmin/B23 , 1999, The Prostate.

[113]  J. Licht,et al.  Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia , 1999, Oncogene.

[114]  B Falini,et al.  Detection of normal and chimeric nucleophosmin in human cells. , 1999, Blood.

[115]  C. Hsu,et al.  Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells , 1998, Oncogene.

[116]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[117]  B. Cullen,et al.  Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay , 1996, Molecular and cellular biology.

[118]  E. Newlands,et al.  Phase I trial of elactocin. , 1996, British Journal of Cancer.

[119]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[120]  S. Raimondi,et al.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. , 1996, Oncogene.

[121]  W. Dinjens,et al.  EXPRESSION OF NUCLEOPHOSMIN/B23 IN NORMAL AND NEOPLASTIC COLORECTAL MUCOSA , 1996, The Journal of pathology.

[122]  P. Chan,et al.  Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. , 1995, Biochimica et biophysica acta.

[123]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[124]  H. Umekawa,et al.  Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. , 1993, Cellular & molecular biology research.

[125]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[126]  Qing-Rong Liu,et al.  Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. , 1989, Biochemistry.

[127]  B. Yung,et al.  Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. , 1987, Biochimica et biophysica acta.